{
    "clinical_study": {
        "@rank": "164790", 
        "arm_group": {
            "arm_group_label": "ticagrelor-prasugrel", 
            "arm_group_type": "Other", 
            "description": "in period 1, 180 mg of ticagrelor will be administrated at a single oral dose. in period 2, 60 mg of prasugrel will be administrated at a single oral dose."
        }, 
        "brief_summary": {
            "textblock": "This study is to characterize the pharmacokinetic and pharmacodynamics of ticagrelor and\n      prasugrel in healthy Korean male subjects.\n\n      The study is open label, one sequence, crossover design. In period 1, a single oral dose of\n      180 mg ticagrelor will be administrated. After at least 7 days washout period, in period 2,\n      a single oral dose of 60 mg prasugrel will be administrated.\n\n      After dosing each period, blood sampling for PK and PD assessment will be conducted.\n\n        1. Blood Sampling Times\n\n             1. PK :predose,10 min,15 min,25 min, 0.5,1,1.5,2,2.5,4,6,8,12 and 24h post-dose\n\n             2. PD :predose,15 min,0.5,1,2,4,6,8,12 and 24h post-dose\n\n        2. Bioanalysis\n\n             1. plasma Ticagrelor\n\n             2. plasma AR-C124910XX (active metabolite of ticagrelor)\n\n             3. plasma R-95913 (inactive metabolite of prasugrel)\n\n             4. plasma R-13727 (active metabolite of prasugrel)\n\n        3. Platelet Aggregation Test using turbidometric Method Maximal Platelet Aggregation(MPA)\n\n        4. PK-PD Modeling analysis"
        }, 
        "brief_title": "PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. male aged 19 - 45 years at screening visit\n\n          2. body weight at least 60 kg at screening visit\n\n          3. body mass index 18 - 30 kg/m2\n\n          4. SBP 90 - 149 mmHg and DBP 60 - 99 mmHg and pulse rate(beat per minute) 45 - 100 at\n             screening visit\n\n        Exclusion Criteria:\n\n          1. any history of or having any clinically significant abnormalities\n\n          2. any gastrointestinal disorder having impact on absorption of study drug\n\n          3. any history of hypersensitivity of ticagrelor or prasugrel or compounds related study\n             drugs\n\n          4. any history of taking original medicines within 30 days before dosing or history of\n             taking prescribed drug within 14 days before dosing or history       of taking OTC\n             drug within 7 days before dosing\n\n          5. any history of taking other study drug within 60 days before dosing\n\n          6. any history of whole blood transfusion within 60 days before dosing or history of\n             blood elements transfusion or history of  heaving been transfused within 30 days\n             before 30 days\n\n          7. any history of taking metabolic inducer or inhibitor\n\n          8. overuse (caffeine: > 5 units/day , alcohol: > 21 units /week, smoking: > 10\n             cigarettes/day)\n\n          9. positive serology testy(Hbs antigen, HIV, Hepatitis C virus, Syphilis)\n\n         10. any abnormality in clinical laboratory tests result or any ECG finding considered to\n             be inadequate by investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876797", 
            "org_study_id": "Hyeong-Seok Lim"
        }, 
        "intervention": {
            "arm_group_label": "ticagrelor-prasugrel", 
            "intervention_name": "ticagrelor/prasugrel", 
            "intervention_type": "Drug", 
            "other_name": [
                "ticagrelor :2 tablets of Brilinta\u00ae 90 mg", 
                "prasugrel : 6 tablets of Effient\u00ae 10 mg"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Prasugrel", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Dose, Open-label, One Sequence, 2-period, Crossover Study to Characterize the Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Male Adult Subjects", 
        "other_outcome": {
            "description": "all adverse event will be collected", 
            "measure": "adverse event monitoring", 
            "safety_issue": "Yes", 
            "time_frame": "up to 1 week"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Hyeong-Seok Lim, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "4 mL of blood will be drawn per each collection", 
            "measure": "plasma ticagrelor parent,AR-C124910XX,R-95913 and R-13727", 
            "safety_issue": "No", 
            "time_frame": "0,10 min,15 min,25 min,0.5h,1h,1.5h,2h,2.5h,4h,6h,8h,12h and 24h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876797"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Hyeong-Seok Lim", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "platelet aggregation will be tested using light transmission aggregometry", 
            "measure": "Maximal Platelet Aggregation(MPA)", 
            "safety_issue": "No", 
            "time_frame": "0,15 min,0.5 min, 1h,2h,4h,8h and 24h"
        }, 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}